Lv67
2130 积分 2023-05-29 加入
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
20天前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
4个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
4个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
4个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
4个月前
已完结
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease
5个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
6个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
6个月前
已完结
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
6个月前
已完结
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
6个月前
已完结
皖公网安备34019202002308
